Annexon, Inc. (ANNX) Stock Price & Analysis

Annexon, Inc. (ANNX) closed at USD 4.01 on Thursday, October 29, 2026, down 0.74% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 4.04; the Oct 29, 2026 session ranged USD 3.95–4.2 on volume of 3,284,752 shares. Market capitalization is $760.21M, with a 52-week range of USD 2.54–7.18 (NMS). Source: Nexqual, retrieved October 29, 2026 at 23:41 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ANNX.md

Key facts (ANNX)

• Insider open-market purchases, last ~7 months: 4 Form 4 filings, $3.5M; 0 by opportunistic insiders, 1 by routine insiders.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 17 (range 7–27).
• Total return with dividends: 1Y +36.9% vs S&P 500 +14.4%; 5Y -75.4% vs S&P 500 +79.1%.
• Next earnings: 2026-11-09 (date not yet confirmed by the company), EPS estimate USD -0.28, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-09
• Dividend: ANNX paid no cash dividend in the last five years.
• Short interest: 17.66% of float (as of 2026-10-15), 9.4 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ANNX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ANNX)

P/B 4.1x · FCF yield -25.42% · Earnings yield -26.66%

Insider purchases (SEC Form 4, open-market, last ~7 months) (ANNX)

4 purchases, $3.5M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ANNX)

Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 17 (low 7, high 27).

Rating changes, last 120 days:

Total return (dividends reinvested) (ANNX)

Dividends (ANNX)

ANNX paid no cash dividend in the last five years.

Short interest (ANNX)

31,627,401 shares sold short, 17.66% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 32,871,995 shares (-3.8%). Days to cover: 9.4 (short shares ÷ average daily volume).

ANNX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ANNX company outlook (results filed Aug 12, 2026)

• “EX-99.1 2 d119960dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies;”
• “BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary Endpoint Strategy and Launch of Open-Label Extension Study;”
• “Month 15 Primary Endpoint on Track for Q4 2026 POC Data for ANX1502, a First-in-Kind Oral C1 Inhibitor for Autoimmune Disease, Expected in Fall 2026 $200 Million Credit Facility Strengthens Balance Sheet and Capabilities;”
• “Anticipated Runway Extended into 2028 Company to Host Business Update Call Today at 8:00 a.m.”

Quoted word-for-word from the SEC 8-K results press release.

ANNX analyst estimates and revisions

ANNX options: expected move

Options price a move of about ±26.0% (±$1.05) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±5.5% on average.

30-day implied volatility 183.5% vs 73.9% realized over the last 30 trading days. Put/call ratio (volume) 0.01. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 23:41 UTC)

Technical Analysis (ANNX)

Nexqual's technical model rates ANNX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 23:41 UTC.

Analyst Ratings (ANNX)

Wall Street analysts rate ANNX "Buy" based on 10 analysts, with a mean price target of USD 17 (range USD 7–27), per Nexqual as of October 29, 2026 at 23:41 UTC.

Earnings (ANNX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 23:41 UTC.

Financials & Fundamentals (ANNX)

Source: Nexqual, October 29, 2026 at 23:41 UTC.

Financial Health Score (ANNX)

Nexqual rates Annexon, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 23:41 UTC.

Ownership (ANNX)

Source: Nexqual, October 29, 2026 at 23:41 UTC.

Leadership (ANNX)

Annexon, Inc. is led by Douglas E. Love Esq., CEO, President & Director, per Nexqual as of October 29, 2026 at 23:41 UTC.

Major Backers & Investors (ANNX)

Notable institutional backers of Annexon, Inc. include FMR, LLC, Fidelity, Redmile Group, LLC, according to Nexqual as of October 29, 2026 at 23:41 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 23:41 UTC.

From Annexon, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• Using our proprietary platform, we are identifying and characterizing the role of the classical complement pathway in three therapeutic areas—autoimmune, neurodegeneration and ophthalmology.
• We filed the Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, for tanruprubart for the treatment of GBS in January 2026, and we continue to engage with EU regulators through the MAA review process.
• We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time.
• Since 2015, we have developed tanruprubart as the potential first targeted therapy for patients with GBS, an acute neurological emergency for which there is no FDA approved treatment.

Partnerships

• To support these Phase 1b and Phase 3 clinical trials conducted at sites outside the United States and based on feedback from the FDA, we conducted a RWE study in collaboration with IGOS investigators to establish comparability between Phase 3 participants and western patients.

Legal & Regulatory Risks (Item 1A, quoted)

• Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
• We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States, the EU or any other jurisdiction.
• Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
• Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 23:41 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt